Steatotic liver disease is being recast as a moving spectrum rather than a set of fixed diagnostic boxes, according to a new global perspective published in Nature Reviews Gastroenterology & Hepatology. The condition, defined by excess fat accumulation in the liver, is increasingly understood as the result of interacting metabolic and alcohol-related pressures that can change over time. Researchers argue that this fluidity has major consequences for how patients are diagnosed, monitored and treated in everyday clinical practice.
The modern classification of steatotic liver disease includes metabolic dysfunction-associated steatotic liver disease, metabolic and alcohol-related liver disease, and alcohol-related liver disease. Although these labels are clinically useful, they do not always reflect the reality experienced by patients. Many people have obesity, type 2 diabetes, hypertension or dyslipidaemia while also consuming alcohol at levels that may influence liver injury. Instead of occupying separate categories, these factors frequently overlap and form a continuous spectrum of risk.
At the centre of this spectrum are cardiometabolic risk factors, or CMRFs. Excess body weight, insulin resistance, abnormal blood lipids, elevated blood pressure and type 2 diabetes can each contribute to hepatic fat accumulation and inflammation. When several are present together, their effects may be synergistic rather than merely additive. Metabolic dysfunction can increase the liver’s vulnerability to alcohol, while alcohol can intensify the biological consequences of obesity and diabetes, creating conditions that promote progressive scarring.
The most serious consequence of this interaction is fibrosis, the accumulation of scar tissue caused by repeated or persistent liver injury. Fibrosis can advance silently for years before cirrhosis develops, and symptoms may remain absent until liver function is substantially impaired. In patients exposed to both metabolic stress and alcohol, progression may be accelerated, increasing the risk of cirrhosis, liver failure and liver-related death. The authors therefore emphasize that alcohol exposure should not be assessed independently from a patient’s metabolic health.
A further challenge is that both alcohol intake and cardiometabolic risk are dynamic. A person’s drinking pattern may increase or decrease, while body weight, blood glucose, blood pressure and lipid levels can change in response to age, illness, medication or lifestyle. These changes may move an individual from one part of the steatotic liver disease spectrum to another. A diagnosis based on a single assessment may consequently become outdated, particularly when clinical decisions depend on rigid thresholds.
Misclassification is also common because alcohol consumption is often under-reported or difficult to quantify accurately. Patients may forget the amount they drink, underestimate serving sizes or avoid disclosure because of stigma. Clinicians, meanwhile, may rely on brief questionnaires that do not fully capture binge drinking, irregular consumption or changes over time. The researchers point to phosphatidylethanol, commonly known as PEth, as an objective biomarker that can help identify recent alcohol exposure. PEth is formed in red blood cells in the presence of alcohol and may provide an important complement to confidential clinical conversations rather than replacing them.
The proposed solution is an integrated form of risk stratification. Instead of asking whether a patient fits a single category, clinicians would systematically evaluate alcohol exposure, cardiometabolic risk and the extent of liver fibrosis. Non-invasive fibrosis assessments, including blood-based scores and imaging techniques that measure liver stiffness, can help identify people at higher risk without immediately requiring a biopsy. Repeated testing is particularly important because the underlying drivers of disease can evolve, altering a patient’s prognosis and treatment needs.
Management under this framework would also be multidimensional. Alcohol reduction or cessation support should be offered alongside intensive treatment of obesity, diabetes, hypertension and dyslipidaemia. Depending on the degree of liver injury, care may involve hepatologists, primary-care physicians, endocrinologists, dietitians, addiction specialists and mental-health professionals. The goal is not simply to reduce fat in the liver, but to interrupt the biological processes that lead to inflammation, fibrosis and cardiovascular complications, which are major causes of illness in people with steatotic liver disease.
The need for a broader approach is becoming more urgent as new liver-directed medicines enter clinical development and practice. Many emerging therapies for metabolic dysfunction-associated steatohepatitis have excluded people with concurrent alcohol use from clinical trials. As a result, the populations studied in trials may not resemble the diverse patients seen in real-world clinics, where metabolic disease and alcohol exposure often coexist. The authors argue that future research and treatment pathways should better reflect this complexity. A spectrum-based model, supported by repeated reassessment and objective measurements where appropriate, could offer a more accurate and equitable way to manage one of the world’s most widespread chronic liver conditions.
Subject of Research: Steatotic liver disease, metabolic and alcohol-related liver risks, cardiometabolic risk factors, fibrosis assessment and integrated patient management.
Article Title: The dynamic spectrum of steatotic liver disease: the global perspective
Article References: Younossi, Z.M., Zelber-Sagi, S., Kalligeros, M. et al. “The dynamic spectrum of steatotic liver disease: the global perspective.” Nature Reviews Gastroenterology & Hepatology (2026). https://doi.org/10.1038/s41575-026-01235-3
Image Credits: AI Generated
DOI: 10.1038/s41575-026-01235-3
Keywords: Steatotic liver disease, metabolic dysfunction-associated steatotic liver disease, alcohol-related liver disease, cardiometabolic risk factors, fibrosis, cirrhosis, phosphatidylethanol, liver health.
